Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3562325?pdf=render |
id |
doaj-0341217466684894a91a62f6d201010c |
---|---|
record_format |
Article |
spelling |
doaj-0341217466684894a91a62f6d201010c2020-11-25T01:45:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5517110.1371/journal.pone.0055171Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.Sukhwinder KaurSubhankar ChakrabortyMichael J BaineKavita MallyaLynette M SmithAaron SassonRandall BrandSushovan GuhaManeesh JainUwe WittelShailender K SinghSurinder K BatraPancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP, n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to HCs. The mean (± standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2), 219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%, respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78% respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9 significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs.http://europepmc.org/articles/PMC3562325?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sukhwinder Kaur Subhankar Chakraborty Michael J Baine Kavita Mallya Lynette M Smith Aaron Sasson Randall Brand Sushovan Guha Maneesh Jain Uwe Wittel Shailender K Singh Surinder K Batra |
spellingShingle |
Sukhwinder Kaur Subhankar Chakraborty Michael J Baine Kavita Mallya Lynette M Smith Aaron Sasson Randall Brand Sushovan Guha Maneesh Jain Uwe Wittel Shailender K Singh Surinder K Batra Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS ONE |
author_facet |
Sukhwinder Kaur Subhankar Chakraborty Michael J Baine Kavita Mallya Lynette M Smith Aaron Sasson Randall Brand Sushovan Guha Maneesh Jain Uwe Wittel Shailender K Singh Surinder K Batra |
author_sort |
Sukhwinder Kaur |
title |
Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. |
title_short |
Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. |
title_full |
Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. |
title_fullStr |
Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. |
title_full_unstemmed |
Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. |
title_sort |
potentials of plasma ngal and mic-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP, n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to HCs. The mean (± standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2), 219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%, respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78% respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9 significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs. |
url |
http://europepmc.org/articles/PMC3562325?pdf=render |
work_keys_str_mv |
AT sukhwinderkaur potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT subhankarchakraborty potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT michaeljbaine potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT kavitamallya potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT lynettemsmith potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT aaronsasson potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT randallbrand potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT sushovanguha potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT maneeshjain potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT uwewittel potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT shailenderksingh potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer AT surinderkbatra potentialsofplasmangalandmic1asbiomarkersinthediagnosisoflethalpancreaticcancer |
_version_ |
1725023807822888960 |